Rare Disease

A new case-control study found that patients with pemphigus vulgaris and bullous pemphigoid face more than twice the odds of comorbid acute stress disorder compared with matched controls.

LEO Pharma shared 2 posters with data from the ongoing EFFISAYIL ON program, supporting long-term use of spesolimab for generalized pustular psoriasis.

The FDA has granted Priority Review to brepocitinib's NDA for dermatomyositis, with a Q3 2026 PDUFA date that could make it the first drug specifically approved for this indication.

This portion of the AMETHYST trial is the second successful phase 2 study of litifilimab, an investigational monoclonal antibody for CLE.

In a patient with longstanding Hailey-Hailey disease, lebrikizumab was associated with rapid improvement in symptoms and quality of life.

A multicenter trial in China shows ALA-PDT clears Bowen’s disease in 97% with low recurrence, minimal scarring, and high patient satisfaction.

February highlights rare genetic skin diseases, shifting dermatology from supportive care to molecularly targeted therapies.

FDA Fast Track boosts hopes for QRX003 lotion in Netherton Syndrome, with early trials showing rapid skin healing and itch relief.

A combined group of ophthalmology and dermatology specialists traveled to communities in Nepal to conduct consultations, procedures, and teaching sessions, and specifically in dermatology, skin malignancy removals, trainings on biologics and JAKs, and melanoma detection demonstrations.

Priovant Therapeutics' brepocitinib has been assigned a Prescription Drug User Fee Act date in the third quarter of 2026.

After TMB-001 did not meet its primary end point in the ASCEND trial, LEO Pharma moved to out-license the vehicle formulation, which unexpectedly provided a response in 40% of patients.

The FDA has assigned a Prescription Drug User Fee Act target action date of December 12, 2026.

In the latest Cutaneous Connection podcast episode, Renata Block, DMSc, MMS, PA-C, and patient advocate Suki Tipp discuss the clinical, emotional, and financial toll of delayed diagnosis of indolent systemic mastocytosis.

Around 800 rare skin diseases affect 6.8 million people worldwide, including epidermolysis bullosa, generalized pustular psoriasis, ichthyosis, and erythropoietic protoporphyria.

Misha Rosenbach, MD, discussed the burden of cutaneous sarcoidosis (CS) and how emerging therapies like brepocitinib could fill this clinical need.

LILAC data shows litifilimab rapidly improves CLE skin scores, fueling AMETHYST phase 3 and supporting FDA breakthrough for cutaneous lupus patients.

Victoria Werth, MD, highlights CLE treatment gaps and how BDCA2-targeting litifilimab may quickly curb interferon-driven skin disease with less toxicity.

Phase 2 BEACON study shows brepocitinib rapidly clears cutaneous sarcoidosis lesions with strong CSAMI gains and tolerability, as Priovant readies phase 3 program.

The FDA’s decision was based on litifilimab’s phase 2 skin disease activity data.

Karen McGuire, PhD, discusses TolaSure, a groundbreaking therapy targeting epidermolysis bullosa simplex, focusing on cellular repair and blister reduction.

Bitopertin shows promise as a disease-modifying therapy for erythropoietic protoporphyria, significantly reducing PPIX levels and improving patient outcomes.

BioMendics is advancing TolaSure in the TAMES-02 trial for EBS, aiming for rapid market access and potential expansion to other keratinopathies.

Quoin Pharmaceuticals seeks Breakthrough Medicine Designation for QRX003, aiming to provide the first treatment for Netherton Syndrome in Saudi Arabia.

Karen McGuire, PhD, discusses innovative TolaSure for treating epidermolysis bullosa simplex, focusing on disease modification rather than symptom management.

Researchers explore CO₂ laser therapy's effectiveness for refractory HHD, revealing its potential to restore skin health and reduce inflammation.